Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Avid Pharmaceuticals

Status and phase: Terminated; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: Florbetapir F 18; Drug: Flortaucipir F18; Procedure: Brain PET Scan

Study type: Interventional

Funder types: Industry

Identifiers

NCT02051764

18F-AV-1451-A04

Details and patient eligibility

About

This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.

Enrollment: 44 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Have a previous 18F-AV-1451 brain scan
• Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
• Ability to provide informed consent

Exclusion criteria

• Current clinically significant psychiatric disease
• Are claustrophobic
• Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes
• Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
• Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
• Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

44 participants in 1 patient group

Follow-up Flortaucipir PET Scan

Experimental group

Treatment:

Procedure: Brain PET Scan

Drug: Flortaucipir F18

Drug: Florbetapir F 18